Merck & Company Inc (MRK)

NYSE
Currency in USD
83.01
-1.41(-1.67%)
Closed
After Hours
83.05+0.04(+0.05%)
MRK Scorecard
Full Analysis
Has raised its dividend for 14 consecutive years
Trading near 52-week Low
Fair Value
Day's Range
82.0984.78
52 wk Range
82.09134.63
Key Statistics
Edit
Prev. Close
84.42
Open
84.42
Day's Range
82.09-84.78
52 wk Range
82.09-134.63
Volume
26.78M
Average Volume (3m)
13.63M
1-Year Change
-34.4%
Book Value / Share
17.59
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MRK Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
116.38
Upside
+40.20%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory
Show more

Merck & Company Inc Company Profile

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Employees
71000

Merck & Company Inc SWOT Analysis


Oncology Dominance
Merck's strong position in oncology, led by Keytruda, faces increasing competition and patent expiration concerns, prompting diversification efforts
Pipeline Potential
Explore Merck's promising pipeline, including Winrevair for PAH and advancements in cardiovascular and immunology treatments
Market Dynamics
Delve into Merck's global market challenges, including the reset of China Gardasil business and the competitive landscape in key therapeutic areas
Financial Outlook
Analyst price targets range from $100 to $155, with EPS projections of $7.79 for FY 2024 and a 3.39% dividend yield
Read full SWOT analysis

Merck & Company Inc Earnings Call Summary for Q3/2024

  • Revenue up 4% to $16.7B; KEYTRUDA sales grew 21% to $7.4B; WINREVAIR launched with $149M sales
  • GARDASIL sales down 10% to $2.3B due to China market; company targets $11B sales by 2030
  • Phase 3 assets nearly tripled; focus on strategic investments for long-term growth
  • 2024 revenue guidance narrowed to $63.6B-$64.1B; 6-7% growth expected with improved margins
  • CEO open to business development; CFO confirms 80%+ of WINREVAIR revenue supports demand
Last Updated: 31/10/2024, 19:48
Read Full Transcript

Compare MRK to Peers and Sector

Metrics to compare
MRK
Peers
Sector
Relationship
P/E Ratio
12.3x−1.9x−0.7x
PEG Ratio
0.000.030.00
Price/Book
4.7x0.7x2.6x
Price / LTM Sales
3.3x2.8x3.1x
Upside (Analyst Target)
37.3%110.7%45.9%
Fair Value Upside
Unlock9.8%8.3%Unlock

Analyst Ratings

18 Buy
9 Hold
0 Sell
Ratings:
27 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 116.38
(+40.20% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 6.74
Dividend Yield
3.84%
Industry Median 1.79%
Annualised payout
3.2400
Paid quarterly
5-Years Growth
+6.96%
Growth Streak

Earnings

Latest Release
Feb 04, 2025
EPS / Forecast
1.72 / 1.81
Revenue / Forecast
15.60B / 15.47B
EPS Revisions
Last 90 days

People Also Watch

169.20
AMAT
-8.18%
55.76
MCHP
+2.76%
156.15
JNJ
-0.70%
172.23
QCOM
+0.05%
423.19
LMT
-2.65%

FAQ

What Is the Merck&Co (MRK) Premarket Price Today?

The Merck&Co (MRK) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 15 Feb 2025. Previous close: 84.42

What Stock Exchange Does Merck&Co Trade On?

Merck&Co is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Merck&Co?

The stock symbol for Merck&Co is "MRK."

What Is the Merck&Co (MRK) Afterhours Price Today? (Afterhours variable test: ) Current Date: 15 Feb 2025

After hours price: . After hours price change (units): . Price change percentage:

What Is the Merck&Co Market Cap?

As of today, Merck&Co market cap is 209.99B.

What is Merck&Co Earnings Per Share?

The Merck&Co EPS is 6.74.

What Is the Next Merck&Co Earnings Date?

Merck&Co will release its next earnings report on 23 Apr 2025.

From a Technical Analysis Perspective, Is MRK a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.